Metal-based drugs that break the rules (Q38714812)

5 September 2017

Metal-based drugs that break the rules (English)

1 reference

5 September 2017

Paul J Dyson

2

0 references

author name string

Claire S Allardyce

series ordinal

1

1 reference

PubMed ID

26820398

5 September 2017

language of work or name

English

0 references

publication date

28 January 2016

1 reference

5 September 2017

1 reference

5 September 2017

45

1 reference

5 September 2017

8

1 reference

5 September 2017

3201-3209

1 reference

Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site

5 September 2017

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Testicular cancer: a narrative review of the role of socioeconomic position from risk to survivorship

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Particular aspects of platinum compounds used at present in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Metal-based antitumour drugs in the post genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Voltage gated ion channels: targets for anticonvulsant drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Epigenetic resensitization to platinum in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Metal complexes, their cellular targets and potential for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Molecular mechanisms of cisplatin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Role of transporters in the distribution of platinum-based drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

The polynuclear platinum BBR3610 induces G2/M arrest and autophagy early and apoptosis late in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Novel bis-platinum complexes endowed with an improved pharmacological profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Ruthenium antimetastatic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

New platinum and ruthenium complexes--the latest class of potential chemotherapeutic drugs--a review of recent developments in the field

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

New trends for metal complexes with anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Approaches to the design of catalytic metallodrugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Organometallic ruthenium(II) arene compounds with antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

NanoSIMS analysis of an isotopically labelled organometallic ruthenium(II) drug to probe its distribution and state in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Metal complexes of curcumin--synthetic strategies, structures and medicinal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Ruthenium(II)–Arene RAPTA Type Complexes Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective Anticancer Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Glutathione S-conjugates as prodrugs to target drug-resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

How acute promyelocytic leukaemia revived arsenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

The novel arsenical darinaparsin is transported by cystine importing systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Employing pancreatic tumor γ-glutamyltransferase for therapeutic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Ludwig Mond Lecture. High-carat gold compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Light in Medicine: The Interplay of Chemistry and Light

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

A requirement for bid for induction of apoptosis by photodynamic therapy with a lysosome- but not a mitochondrion-targeted photosensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Photocatalytic generation of oxygen radicals by the water-soluble bacteriochlorophyll derivative WST11, noncovalently bound to serum albumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Apoptotic response to photodynamic therapy versus the Bcl-2 antagonist HA14-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Molecular combo of photodynamic therapeutic agent silicon(iv) phthalocyanine and anticancer drug cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Systems biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

The combined therapeutical effect of metal-based drugs and radiation therapy: the present status of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Metalloporphyrin class of therapeutic catalytic antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

From conventional to unusual enzyme inhibitor scaffolds: the quest for target specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Targeting the undruggable proteome: the small molecules of my dreams

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

High precision multi-genome scale reannotation of enzyme function by EFICAz

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Liposomal drug delivery systems: from concept to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

The development of RAPTA compounds for the treatment of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

Spectral characterization of ruthenium(III) transferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5DT03919C

21 January 2018

Identifiers

DOI

10.1039/C5DT03919C

1 reference

5 September 2017

1 reference

PubMed ID

26820398